With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more
NVO is expected to report earnings to fall 24.86% to 78 cents per share on August 05
Q2'26
Est.
$0.78
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.10
Q3'25
Missed
by $0.09
Q2'25
Est.
$0.93
The last earnings report on May 06 showed earnings per share of $1.04, missing the estimate of $1.09. With 2.83M shares outstanding, the current market capitalization sits at 215.77B.